Dermatology News and Research

Latest Dermatology News and Research

Acne patients not getting medications prescribed by their dermatologists

Medicine obviously can't do much good if it sits on a pharmacy shelf. Yet more than one-quarter of the acne patients surveyed by Wake Forest Baptist Medical Center researchers didn't get medications prescribed by their dermatologists.

23 Mar 2015

Study: Blood tests for women taking spironolactone to treat hormonal acne are unnecessary

A new study by researchers at Brigham and Women's Hospital has found that for young, healthy women taking spironolactone to treat hormonal acne, frequent office visits and blood draws are an unnecessary health care expense.

23 Mar 2015

Cosentyx (secukinumab) safe, effective for treating psoriasis patients

Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes from the extension study of the pivotal Phase III FIXTURE and ERASURE trials.

21 Mar 2015

Alma Lasers launches Harmony XL Pro platform to address aesthetic concerns of patients

Alma Lasers, a global innovator of laser, light-based, radiofrequency and ultrasound solutions for the aesthetic and surgical markets announced the addition of the Harmony XL Pro platform to its product portfolio.

20 Mar 2015

NeoStrata announces launch of SKIN ACTIVE Dermal Replenishment

NeoStrata Company, Inc., today announced the launch of SKIN ACTIVE Dermal Replenishment, an intense hydrator that delivers a powerful four-pronged anti-aging approach.

20 Mar 2015

Spironolactone drug reduces side effects of corticosteroid-based dermatological creams

Basic research on blood pressure has led researchers from Inserm (Inserm Unit 1138, "Cordeliers Research Centre") to obtain unexpected results: drugs used to treat hypertension (high blood pressure) reduce side effects from corticosteroid-based creams used to treat certain skin diseases.

19 Mar 2015

New antibody treatment blocks immune signaling protein crucial to psoriasis

Many patients suffering from psoriasis showed significant recovery after just a single dose of an experimental treatment with a human antibody that blocks an immune signaling protein crucial to the disease, researchers report.

16 Mar 2015

Mechanistic subtypes of IPAH revealed

Researchers have provided evidence for distinct processes underlying vasodilator-responsive and nonresponsive idiopathic pulmonary arterial hypertension.

13 Mar 2015

Combining CT measurements assists pulmonary hypertension prediction

Research suggests that combining pulmonary artery and ventricular measurements improves the chances of identifying pulmonary hypertension in patients undergoing computed tomography pulmonary angiography.

13 Mar 2015

Metabolic derangement may facilitate cell proliferation in PAH

An enzyme that facilitates modification of proteins via a glucose metabolism pathway may promote cell proliferation in the lung tissue of patients with idiopathic pulmonary arterial hypertension, say researchers.

13 Mar 2015

Prognostic potential for pericardial effusion in PAH patients

Monitoring pericardial effusion on serial transthoracic echocardiograms provides useful prognostic information in patients with pulmonary arterial hypertension, research suggests.

13 Mar 2015

New study identifies genetic factors for rosacea

Today marked the publication of the first ever genome-wide association study of rosacea, a common and incurable skin disorder. Led by Dr. Anne Lynn S. Chang of Stanford University's School of Medicine, and co-authored by 23andMe, the study is the first to identify genetic factors for this condition.

11 Mar 2015

Myriad Publishes myPath™ Melanoma Pivotal Validation Study in the Journal of Cutaneous Pathology

Myriad Genetics, Inc. (NASDAQ: MYGN) today announced the Journal of Cutaneous Pathology published data from a pivotal clinical validation study that showed the myPath™ Melanoma test is highly effective at differentiating benign skin moles from malignant melanoma with greater than 90 percent diagnostic accuracy. Melanoma is the most dangerous type of skin cancer and more than 76,000 new cases of melanoma are diagnosed each year in the United States.

6 Mar 2015

Good news for patients suffering from shingles

The Journal of Drugs in Dermatology is delighted to present new findings from the Mayo Clinic's Department of Dermatology showing possible relief from the complications and pain secondary to Herpes Zoster, commonly known as shingles.

5 Mar 2015

Pediatric Cancer Genome Project identifies genetic basis of three pediatric melanoma subtypes

The St. Jude Children's Research Hospital—Washington University Pediatric Cancer Genome Project found that melanoma in some adolescent and adult patients involves many of the same genetic alterations and would likely respond to the same therapy.

5 Mar 2015

Physicians urge households to add 'clean my medicine cabinet' to Spring cleaning chores list

After marijuana and alcohol, the most commonly abused drugs by those over the age of 14 are prescription and over-the-counter medications.

28 Feb 2015

Cipher acquires worldwide rights to three products from Astion

Cipher Pharmaceuticals Inc. today announced it has strengthened its product pipeline by acquiring the worldwide rights to three products from Astion Pharma, a Denmark-based specialty pharmaceutical company.

26 Feb 2015

Psoriasis management: an interview with Dr Sandy McBride

A major challenge around treating psoriasis is communication - psoriasis can flare and resolve in between appointments so it can be difficult to express and describe the life impact of these flares and recall possible triggers and response to treatments. People with psoriasis can also find it very difficult to talk about their emotions – something known as alexithymia – again making it difficult for clinicians to fully appreciate the impact of psoriasis.

25 Feb 2015

FDA approves Cynosure's new 532 nm Laser Delivery System for PicoSure

Cynosure, Inc. today announced FDA 510(k) clearance of its new 532 nm Laser Delivery System for PicoSure, creating a powerful, dual-wavelength laser system for removing tattoos of all colors in fewer treatments. PicoSure, the world's first picosecond aesthetic laser, is widely recognized for its technology leadership, unmatched clinical versatility and proven performance.

25 Feb 2015

RepliCel submits CTA for RCS-01 study to treat patients suffering from aged, UV-damaged skin

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced the submission of a Clinical Trial Application (CTA) to the German Competent Authority, the Paul-Ehrlich-Institut (PEI), requesting clearance to initiate a Phase 1 clinical trial investigating the use of RCS-01 to treat patients suffering from aged and UV-damaged skin.

23 Feb 2015